Treatment of heart failure in patients aged 75 years or older: Comparison with younger patients;Tratamiento de la insuficiencia cardíaca en pacientes mayores de 75 años. Estudio comparativo con los pacientes ḿas jóvenes

Revista Espanola de Geriatria y Gerontologia

Volumn 41, Issue 5, 2006, Pages 264-269

  Urrutia, Agustín ^a   Lupón, Josep ^a   Altimir, Salvador ^a   González, Beatriz ^a   Herreros, Joan ^a   Díez, Crisanto ^a   Coll, Ramón ^a   Valle, Vicente ^a   Rey Joly, Celestino ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Heart failure; Old old; Treatment

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

EID: 33750630566     PISSN: 0211139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0211-139X(06)72971-7     Document Type: Article

References (18)

1. MERIT-HP Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet. 1999;353:2001-7.
2. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
3. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
4. Simon T, Mary-Krause M, Funck-Brentano C, Lechat Ph, Jaillon P, on behalf of CIBIS II investigators. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J. 2003;24:552-9.
5. Hülsmann M, Berge R, Mortl D, Pacher R. Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey. Eur J Heart Fail. 2005;7:657-61.
6. Hunt SA. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1-82.
7. Remme WJ, Swedberg K, for the Task force for the diagnosis and treatment of Chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-60.
8. Altimir S, Lupón J, González B, Prats M, Parajón T, Urrutia A, et al. Sex and age differences in frailty in a heart failure population. Eur J Heart Fail. 2005;7:798-802.
9. Lund LH, Mancini D. Heart failure in women. Med Clin North Am. 2004;88:1321-45.
10. Kannel WB. Incidence and epidemiology of heart failure. Heart Failure Reviews. 2000;5:167-73.
11. Anguita Sanchez M y los investigadores del grupo BADAPIC. Características clínicas, tratamiento y morbimortalidad a corto plazo de pacientes con insuficiencia cardíaca controlados en consultas específicas de insuficiencia cardíaca. Resultados del Registro BADAPIC. Rev Esp Cardiol. 2004;52:1159-69.
12. Ruiz M, Anguita M, De Zayas R, Bergillos F, Torres F, Gimenez D, et al. Características y evolución de los pacientes mayores de 65 años con insuficiencia cardíaca severa. Rev Esp Cardiol. 1996;49:253-8.
13. Maison P, Cunin P, Hemery F, Fric F, Elie N, Del Volgo A, et al. Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study. Eur J Clin Pharmacol. 2005;61:445-51.
14. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al, The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2005;24:46a-7.
15. Swedberg K, Cleland J, Dargie H, Drexler H, Follam F, Komajda M, et al. for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115-40.
16. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703.
17. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87 Suppl:VI102-10.
18. White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, et al for the VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005;112:3391-9.